NDAORALCAPSULE
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORABID (loracarbef) is an oral second-generation cephalosporin antibiotic approved in 1991 for bacterial infections. It is administered as a capsule and represents a small-molecule beta-lactam antibiotic class agent. The drug treats community-acquired infections across respiratory, urinary, and skin/soft tissue indications.
LOE Approaching
Declining
Declining commercial opportunity; small team focus on generic transition planning and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LORABID offers limited career advancement in a legacy, declining product with minimal linked job opportunities. Suitable roles focus on compliance, transition planning, and cost management rather than growth or innovation.
Brand Manager (legacy support)Regulatory Affairs Specialist
Worked on LORABID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.